Additionally, there is a switching of HER2-low status in progressive disease—a retrospective study of LumB BC patients showed that there was extensive switching between HER2-low and HER2-0 status at a rate of 34% or 25% in either direction (90). Here, ERBB2 is linked to breast cancer.